{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:18:05Z","timestamp":1778609885230,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41391-018-0055-8","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T10:46:45Z","timestamp":1528282005000},"page":"516-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis"],"prefix":"10.1038","volume":"21","author":[{"given":"Pui San","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Pedro","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"55_CR2","unstructured":"WHO. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, World Health Organization. 2012. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx ."},{"key":"55_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL,Miller KD,Jemal A, Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"55_CR4","unstructured":"American Cancer Society. Survival rates for prostate cancer. 2017. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html Accessed 10 Sep 2017."},{"key":"55_CR5","unstructured":"Huggins C, Hodges CV Studies on Prostatic Cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1. http:\/\/cancerres.aacrjournals.org\/content\/1\/4\/293 Accessed 10 Sep 2017."},{"issue":"2","key":"55_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","author":"CHARLES HUGGINS","year":"1941","unstructured":"Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209\u201323. https:\/\/doi.org\/10.1001\/archsurg.1941.01210140043004 .","journal-title":"Archives of Surgery"},{"issue":"suppl 5","key":"55_CR7","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","volume":"26","author":"C. Parker","year":"2015","unstructured":"Parker C, Gillessen S, Heidenreich A, Horwich A. cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v69\u201377. https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mdv222 .","journal-title":"Annals of Oncology"},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1704174 .","journal-title":"N Engl J Med"},{"key":"55_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, Open-label, Phase 3 trial. Lancet Oncol. 2013;14:149\u201358.","journal-title":"Lancet Oncol"},{"key":"55_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis G, Boher JM, Joly F, Souli\u00e9 M, Albiges L, Priou F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70:256\u201362.","journal-title":"Eur Urol"},{"issue":"8","key":"55_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"Christopher J. Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1503747 .","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"55_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","volume":"22","author":"Tomomi Kamba","year":"2016","unstructured":"Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y. A phase III multicenter, randomized, contro lled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. Int J Clin Oncol. 2017;22:166\u201373.","journal-title":"International Journal of Clinical Oncology"},{"key":"55_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). J Clin Oncol. 2014;32:1143\u201350.","journal-title":"J Clin Oncol"},{"key":"55_CR14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","volume":"10","author":"DP Dearnaley","year":"2009","unstructured":"Dearnaley DP,Mason MD,Parmar MKB,Sanders K,Sydes MR, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10:872\u20136. https:\/\/doi.org\/10.1016\/S1470-2045(09)70201-3 .","journal-title":"Lancet Oncol"},{"issue":"17","key":"55_CR15","first-page":"1300","volume":"95","author":"D. P. Dearnaley","year":"2003","unstructured":"Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson ACR, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95:1300\u201311. https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djg038 .","journal-title":"CancerSpectrum Knowledge Environment"},{"key":"55_CR16","doi-asserted-by":"crossref","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone the rapy. N Engl J Med. 2017;377:338\u201351. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1702900 .","DOI":"10.1056\/NEJMoa1702900"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"55_CR18","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","volume":"35","author":"MD Mason","year":"2017","unstructured":"Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, et al. Adding celecoxib with or without zoledronic acid for hormone-na\u00efve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol. 2017;35:1530\u201341.","journal-title":"J Clin Oncol"},{"issue":"2","key":"55_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"Georgia Salanti","year":"2011","unstructured":"Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163\u201371. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20688472 .","journal-title":"Journal of Clinical Epidemiology"},{"key":"55_CR20","unstructured":"Plummer M. RJAGS version 3-11: Bayesian graphical models using MCMC. 2012."},{"key":"55_CR21","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2017. https:\/\/www.r-project.org\/ . Accessed March 2017."},{"key":"55_CR22","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D,Liberati A,Tetzlaff J,Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med [Internet]. 2009;6:e1000097. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2707599&tool=pmcentrez&rendertype=abstract .","journal-title":"PLoS Med [Internet]"},{"key":"55_CR23","unstructured":"Matthew RS et al. LBA31_PR - Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476). ESMO. 2017. http:\/\/www.esmo.org\/Oncology-News\/Adding-abiraterone-acetate-or-docetaxel-plus-prednisone-to-standard-of-care-in-patients-with-high-risk-prostate-cancer . Accessed 11 Sep 2017."},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","volume":"84","author":"Larysa H.M. Rydzewska","year":"2017","unstructured":"Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017;84:88\u2013101. http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311103 .","journal-title":"European Journal of Cancer"},{"issue":"feb05 1","key":"55_CR25","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1136\/bmj.c221","volume":"340","author":"R. D. Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. http:\/\/www.bmj.com\/cgi\/doi\/10.1136\/bmj.c221 .","journal-title":"BMJ"},{"key":"55_CR26","unstructured":"ClinicalTrials.gov. A Phase III of ADT\u2009+\u2009\/\u2212 Docetaxel\u2009+\u2009\/- Local RT\u2009+\u2009\/\u2212 Abiraterone Acetate in Metastatic Hormone-na\u00efve Prostate Cancer. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01957436 . Accessed 11 Sep 2017."},{"key":"55_CR27","unstructured":"ClinicalTrials.gov. Enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02446405 . Accessed 11 Sep 2017."},{"key":"55_CR28","unstructured":"ClinicalTrials.gov. A study of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02677896 . Accessed 11 Sep 2017."},{"key":"55_CR29","unstructured":"ClinicalTrials.gov. ODM-201 in addition to standard ADT and docetaxel in metastatic castration sensitive prostate cancer. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02799602 . Accessed 11 Sep 2017."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0055-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0055-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0055-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:15Z","timestamp":1684618395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-018-0055-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1038\/s41391-018-0055-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"assertion":[{"value":"10 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}